APIK Journal of Internal Medicine

LETTER TO THE EDITOR
Year
: 2021  |  Volume : 9  |  Issue : 4  |  Page : 273--274

Circulating cell-free DNA biomarkers


Jose Rafael Villarreal Escorcia 
 Department of Epidemiology, Autonomous University of Bucaramanga, Bucaramanga, Colombia

Correspondence Address:
Dr. Jose Rafael Villarreal Escorcia
Postgraduate in Epidemiology, Cr 65# 56 -39, Itagui
Colombia




How to cite this article:
Escorcia JR. Circulating cell-free DNA biomarkers.APIK J Int Med 2021;9:273-274


How to cite this URL:
Escorcia JR. Circulating cell-free DNA biomarkers. APIK J Int Med [serial online] 2021 [cited 2022 Jan 24 ];9:273-274
Available from: https://www.ajim.in/text.asp?2021/9/4/273/328686


Full Text



Sir,

The strokes have been a challenge for doctors and have become one of the main causes of death and disability in the world,[1] even with trained staff, imaging technologies, and appropriate hospitals, since clinical suspicion in the early stages of the event is difficult, as is the determination of severity. Consequently, possible biomarkers have been investigated in the peripheral blood of patients with a cerebrovascular accident, but none have found a place in clinical practice due to the lack of specificity and sensitivity, easy access, cost-effectiveness ratio, or protocols adapted to international guidelines, at this time, there is no consensus on a routine basis recommendation.

In an article recently published by Kulkarni,[2] an attempt is made to give a brief review of the biomarkers associated with stroke, but leaves aside the determination of circulating cell-free DNA which has been widely studied and cited in multiple articles is not mentioned, said fragments are released shortly after cell death and rupture of the blood–brain membrane in both ischemic and hemorrhagic cerebrovascular disease, with ease for its determination by polymerase chain reaction, correlating with the severity of the cerebrovascular event.[3],[4]

In the cited article, the biomarker is excluded from the possible options for future research, we recommend increasing the clinical evidence taking into account its promising use is underestimated, however, the author's effort is acknowledged since it shares a general but clear vision of the possibilities to use biomarkers in cerebrovascular disease, revealing the limitations for their present-day use.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Bustamante A, Mancha F, Macher HC, García-Berrocoso T, Giralt D, Ribó M, et al. Circulating cell-free DNA is a predictor of short-term neurological outcome in stroke patients treated with intravenous thrombolysis. J Circ Biomark 2016;5:1-6.
2Kulkarni GB. Biomarkers in assessing the severity of stroke. APIK J Internal Med 2021;9:137-8.
3Vajpeyee A, Wijatmiko T, Vajpeyee M, Taywade O, Pandey S, Chauhan PS, et al. Clinical usefulness of cell-free DNA as a prognostic marker in acute ischemic stroke. Neurologist 2020;25:11-3.
4Pös Z, Pös O, Styk J, Mocova A, Strieskova L, Budis J, et al. Technical and methodological aspects of cell-free nucleic acids analyzes. Int J Mol Sci 2020;21:E8634.